Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,164.00
Bid: 12,160.00
Ask: 12,164.00
Change: 68.00 (0.56%)
Spread: 4.00 (0.033%)
Open: 12,150.00
High: 12,286.00
Low: 12,134.00
Prev. Close: 12,096.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-EU chief faces grilling over shaky COVID-19 vaccine strategy

Tue, 02nd Feb 2021 17:36

* EU under fire over slow vaccine rollout, border checks
issue

* Von der Leyen says Commission has been 'quick on its feet'

* Sees easing of supply problems as production ramps up
(Updates after meetings)

By Philip Blenkinsop

BRUSSELS, Feb 2 (Reuters) - EU lawmakers questioned chief
executive Ursula von der Leyen for hours on Tuesday over the
slow rollout and shortage of COVID-19 vaccines as she took
responsibility for an export control plan that angered Britain
and Ireland.

Three groups in the European Parliament on Tuesday evening
grilled Von der Leyen, a German who tweeted and appeared only on
German television in the first few days after the bloc imposed
curbs on vaccine exports on Friday.

Another parliament session was set for Wednesday morning,
and the groups want the EU president to appear before a full
session of parliament next week.

The COVID-19 vaccine crisis, which came to a head with the
EU export controls, followed news that AstraZeneca would
cut its supply of vaccines to the bloc until March by 60% due to
production problems.

Even with the addition of an extra 9 million doses that von
der Leyen announced on Sunday, the shortfall is at least 50%.

Questions still surround the Commission's decision -
swiftly reversed - to invoke Article 16 of the Brexit
agreement's Northern Ireland protocol. The move, part of the
EU's effort to boost vaccine supply for its member states, would
have set up border checks on the island of Ireland.

Von der Leyen accepted responsibility for Commission acts
and decisions, a person at one of Tuesday's meetings said.

The European Commission president repeated to lawmakers
arguments she made to newspapers as she sought to defuse
criticism over the slow start to COVID-19 vaccinations and
outrage over the border checks issue.

Asked by the Irish Times if she would apologise, von der
Leyen said she regretted that Article 16 was in a "provisional
version" of the decision, but said the EU executive had been
"quick on its feet" to find another solution.

Dacian Ciolos, president of the liberal Renew Europe group,
said mistakes could have grave consequences. "We have no margin
for error in this process. Not only does the credibility of the
EU and in particular the European Commission depend on it but
also the health and wellbeing of our citizens," he said in a
statement.

Sophie in 't Veld, a Dutch liberal lawmaker, said von der
Leyen was relying on too narrow a circle of advisers.

"She's made a couple of big fat mistakes. Article 16 was
one," she told Reuters, adding that her tendency to speak only
to German media was another problem.

EU countries have so far given first doses to about 3% of
their populations, compared with 9% for the United States and
14% for Britain, according to Our World in Data.

Von der Leyen said the EU had lagged rivals by three to four
weeks because of a more rigorous approvals process. Supply
problems should ease in the second quarter of 2021, but
increasing production remained a challenge.
(Reporting by Philip Blenkinsop; additional reporting by John
Chalmers
Editing by Gareth Jones, Angus MacSwan and Cynthia Osterman)

More News
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.